MAPT and prion disease: In the gCJD group, there were no significant differences in p-tau levels between V210I-129M and E200K-129M carriers (p = 0.111), while the single case of VPSPr showed one of the highest CSF p-tau levels of the prion disease group (140 pg/ml).